$HROW

HARROW, INC. (HROW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer

Harrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

Harrow, Inc. (HROW) reported that its IHEEZO gel reduced patient discomfort by 58% compared to proparacaine in a study of 50 patients. The FDA-approved anesthetic showed statistically significant benefits at all assessment points. HROW stock closed at $41.64, up 5.36%, and was at $41.95 in pre-market trading.

Harrow (HROW) reported Q2 2026 revenue of $70.7M, up 11% YoY, with first-half revenue at $115M. Key products IHEEZO and VEVYE showed growth, with IHEEZO achieving record unit demand and VEVYE seeing a 21% sequential prescription increase. The company expects stronger revenue and profitability in the second half, driven by improved product economics, broader commercial coverage, and strategic acquisitions like TYRVAYA. Harrow reiterated its full-year guidance, anticipating sequential revenue grow

Shojaei Amir (CHIEF SCIENTIFIC OFFICER) sold 11,250 shares of HARROW, INC. (HROW) at $40.00 ($0.45M total) on 2026-08-14.

Harrow, Inc. (HROW) reported a Q2 loss of $17.3 million, or 46 cents per share. Adjusted losses were 34 cents per share. The company’s revenue was $70.7 million, below Zacks-surveyed expectations of $71.1 million and a forecast loss of 23 cents per share. Results missed Wall Street estimates, according to Zacks data.

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: ● Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year ● Reiterated full-year 2026 financial guidance of $350 million to $365 mi

HARROW, INC. (HROW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Harrow Acquires Global Rights to TYRVAYA ® , the First and Only FDA-Approved Nasal Spray for Dry Eye Disease NASHVILLE, Tenn., August 6, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that